stroke

[Genome Research] Together with information from genome-wide association studies or vascular disease traits, scientists tested the ability of 34,344 variants to perturb enhancer function in endothelial cells using the highly multiplexed STARR-seq assay.

[Acticor Biotech] Acticor Biotech announced positive results from its ACTIMIS Phase Ib/IIa clinical trial using glenzocimab as an add-on to standard of care in patients with AIS.

[Biophysical Journal] Investigators found that AGA(C8R)-HNG17 confered protection against necrosis in neuronal cell lines PC-12 and NSC-34, where necrosis was induced in a glucose-free medium by either chemohypoxia or by a shift from apoptosis to necrosis.

[Histology and Histopathology] Investigators review the levels of S1P in those vascular and vascular-related diseases. Plasma S1P levels were reduced in various inflammation-related diseases such as atherosclerosis and sepsis, but were increased in other diseases including type 2 diabetes, neurodegeneration, and cerebrovascular damage.

[Stem Cell Reviews and Reports] The authors unveiled the role of MSCs in regulating the brain sirtuin-1 (SIRT-1) levels following stroke and the involvement of SIRT-1 in regulating inflammasome signaling to reduce cellular apoptosis towards rendering neuroprotection.

[Leonhardt Ventures (Globe Newswire, Inc.)] Leonhardt Ventures LLC announced that it has begun an active research program to combine its patent-pending klotho expression bioelectric stimulation technologies with newly acquired klotho expressing MSC technology.